

FLOURISH PHARMA

BRAND NAME:	AGS PREGABLIN CAPSULE
GENERIC NAME:	PREGABLIN CAPSULE BP 300mg

1. Name of medicinal product

PREGABALIN CAPSULE 300 MG

1.1 (Trade) name of product: AGS PREGABLIN CAPSULE

1.2 Strength

Each hard gelatin

capsule contains

Pregabalin BP 300 mg

Excipients q.s.

1.3 Pharmaceutical Dosage Form –Tablets for oral administration

2. QUALITATIVE & QUANTITATIVE COMPOSITION

2.1 Qualitative Declaration

Each hard gelatin capsule contains

Pregabalin BP 300 mg

Excipients q.s.

2.2 Quantitative Declaration

Batch Formula:

Batch Size: 10,000 Tablets

FLOURISH PHARMA

BRAND NAME:	AGS PREGABLIN CAPSULE
GENERIC NAME:	PREGABLIN CAPSULE BP 300mg

INGREDIENTS	SPEC.	QTY./CAPSULE (IN MG)	OVERAGES	STD. QTY. (IN KG)
Pregabalin	BP	300.00	-	30.000
Starch	BP	124.50	-	12.45
Talc	BP	25.00	-	2.500
Magnesium Stearate	BP	20.00	-	2.000
Colloidal Anhydrous Silica	BP	2.50	-	0.250
EHG Capsules Size-1 red cap/ white body	IH	1.00 Nos	-	102000

3. Pharmaceutical Form:

Solid Oral .A hard gelatin capsule with Red cap with off white body with white crystalline powder

4. Clinical Particulars

4.1 Indication

Neuropathic pain

It is indicated for the treatment of peripheral and central neuropathic pain in adults.

Epilepsy

It is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.

Generalised anxiety disorder

It is indicated for the treatment of Generalised Anxiety Disorder (GAD) in adults.

4.2 Posology and Administration

Posology

The dose range is 150 to 600 mg per day given in either two or three divided doses.

Neuropathic pain

BRAND NAME:	AGS PREGABLIN CAPSULE
GENERIC NAME:	PREGABLIN CAPSULE BP 300mg

Pregabalin treatment can be started at a dose of 150 mg per day given as two or three divided doses. Based on individual patient response and tolerability, the dose may be increased to 300 mg per day after an interval of 3 to 7 days, and if needed, to a maximum dose of 600 mg per day after an additional 7-day interval.

Epilepsy

Pregabalin treatment can be started with a dose of 150 mg per day given as two or three divided doses.

Based on individual patient response and tolerability, the dose may be increased to 300 mg per day after

1 week. The maximum dose of 600 mg per day may be achieved after an additional week.

4.3 Contraindication

Hypersensitivity to the active substance or to any of the excipients

4.4 Special Warning & precautions for use

Diabetic patients

In accordance with current clinical practice, some diabetic patients who gain weight on pregabalin treatment may need to adjust hypoglycaemic medicinal products.

Hypersensitivity reactions

There have been reports in the postmarketing experience of hypersensitivity reactions, including cases of angioedema. Pregabalin should be discontinued immediately if symptoms of angioedema, such as facial, perioral, or upper airway swelling occur.

Dizziness, somnolence, loss of consciousness, confusion and mental impairment

Pregabalin treatment has been associated with dizziness and somnolence, which could increase the occurrence of accidental injury (fall) in the elderly population. confusion and mental impairment.

Therefore, patients should be advised to exercise caution until they are familiar with the potential effects of the medicinal product.

4.5 Interaction with other medicinal products and other forms of interaction

Since pregabalin is predominantly excreted unchanged in the urine, undergoes negligible metabolism in humans (< 2% of a dose recovered in urine as metabolites), does not inhibit drug metabolism in vitro, and is not bound to plasma proteins, it is unlikely to produce, or be subject to, pharmacokinetic interactions.

4.6 Fertility, Pregnancy and lactation

It should not be used during pregnancy unless clearly necessary.

BRAND NAME:	AGS PREGABLIN CAPSULE
GENERIC NAME:	PREGABLIN CAPSULE BP 300mg

4.7 Effects on ability to drive and use machines

It may have minor or moderate influence on the ability to drive and use machines. It may cause dizziness and somnolence and therefore may influence the ability to drive or use machines. Patients are advised not to drive, operate complex machinery or engage in other potentially hazardous activities until it is known whether this medicinal product affects their ability to perform these activities.

4.8 Undesirable effects

The most commonly reported adverse reactions during treatment are somnolence, dizziness, headache, palpitations, flushing, abdominal pain, nausea, ankle swelling, oedema and fatigue.

4.9 Overdose

The most commonly reported adverse reactions observed when pregabalin was taken in overdose included somnolence, confusional state, agitation, and restlessness. Seizures were also reported.

In rare occasions, cases of coma have been reported.

Treatment of pregabalin overdose should include general supportive measures and may include haemodialysis if necessary.

5. Pharmacological properties

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Anti-epileptics, other anti-epileptics ATC code: N03AX16

The active substance, pregabalin, is a gamma-aminobutyric acid analogue [(S)-3-(aminomethyl)-5-methylhexanoic acid].

Mechanism of action

Pregabalin binds to an auxiliary subunit ($\alpha 2$ - δ protein) of voltage-gated calcium channels in the central nervous system.

5.2 Pharmacokinetic properties

BRAND NAME:	AGS PREGABLIN CAPSULE
GENERIC NAME:	PREGABLIN CAPSULE BP 300mg

Pregabalin steady-state pharmacokinetics are similar in healthy volunteers, patients with epilepsy receiving anti-epileptic drugs and patients with chronic pain.

Absorption

Pregabalin is rapidly absorbed when administered in the **fasted state, with peak plasma** concentrations occurring within 1 hour following both single and multiple dose administration. Pregabalin oral bioavailability is estimated to be $\geq 90\%$ and is independent of dose. Following repeated administration, steady state is achieved within 24 to 48 hours. The rate of pregabalin absorption is decreased when given with food resulting in a decrease in C_{max} by approximately 25-30% and a delay in t_{max} to approximately 2.5 hours. However, administration of pregabalin with food has no clinically significant effect on the extent of pregabalin absorption.

Distribution

In humans, the apparent volume of distribution of pregabalin following oral administration is approximately 0.56 l/kg. Pregabalin is not bound to plasma proteins.

Biotransformation

Pregabalin undergoes negligible metabolism in humans. Following a dose of radiolabelled pregabalin, approximately 98% of the radioactivity recovered in the urine was unchanged pregabalin. The N-methylated derivative of pregabalin, the major metabolite of pregabalin found in urine, accounted for 0.9% of the dose. In preclinical studies, there was no indication of racemisation of pregabalin S-enantiomer to the R-enantiomer.

Elimination

Pregabalin is eliminated from the systemic circulation primarily by renal excretion as unchanged drug. Pregabalin mean elimination half-life is 6.3 hours. Pregabalin plasma clearance and renal clearance are directly proportional to creatinine clearance

6. Pharmaceutical particulars

6.1 List of excipients

Starch
Talc
Colloidal Anhydrous Silica
Magnesium Stearate

6.2 Incompatibilities

Not Applicable

6.3 Shelf Life

FLOURISH PHARMA

BRAND NAME:	AGS PREGABLIN CAPSULE
GENERIC NAME:	PREGABLIN CAPSULE BP 300mg

36 months

6.4. Special precaution for Storage

Do not store above 30°C.

6.5. Nature and contents of container

10 X 15 capsules in Alu-Pvc Blister pack in a carton along with insert.

7. Marketing Holder

Anyi Gold Global Serivices Ltd
Nigeria

8. Marketing authorization number(s)

9. Date of first authorisation/renewal of the authorisation

10. Date of revision of the text